Business Context and Reporting Period
This Form 6-K filing by Inventiva S.A. covers the month of December 2024. The Company is a clinical-stage biopharmaceutical entity focused on the development of lanifibranor for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis). The filing primarily details the execution of the second phase of the first tranche of a multi-tranche private placement financing.
Key Financial Metrics
The filing does not provide historical revenue, profit, or cash flow statements for the period. Key financial data relates to the new financing transaction:
- Gross Proceeds: Expected to be €21.4 million from the issuance of T1 bis Securities.
- Net Proceeds: Expected to be €20.1 million.
- Securities Issued: 7,872,064 ordinary shares and 8,053,847 pre-funded warrants.
- Subscription Price: €1.35 per ordinary share; €1.34 per pre-funded warrant.
- Use of Proceeds: Approximately 85% allocated to the NATiV3 clinical program for lanifibranor (MASH treatment) and potential New Drug Application (NDA) submission; 15% for general corporate purposes.
Material Changes
Significant corporate and financial changes occurred in December 2024:
- Financing Execution: Following shareholder approval on December 11, 2024, the Company entered into the "T1 bis Subscription Agreement" on December 13, 2024, advancing the Multi-Tranche Financing.
- Board Composition: Mark Pruzanski, M.D., and Srinivas Akkaraju, M.D., Ph.D., were appointed to the Board of Directors. Dr. Pruzanski was appointed Chairperson. Concurrently, Sofia BV (represented by Chris Buyse) and Pierre Broqua resigned as directors on December 10, 2024.
- Future Governance: The Company agreed to nominate up to four additional Board members proposed by investors at the next annual general meeting or by December 31, 2025.
Outlook, Risks, and Contingencies
Management's outlook is contingent upon the successful completion of the financing and clinical trials. Key risks and contingencies include:
- Clinical Trial Risks: The Company cannot guarantee that the NATiV3 trial results will be available on the anticipated timeline or support regulatory approval. A previously announced Suspected Unexpected Serious Adverse Reaction (SUSAR) may impact enrollment or trial results.
- Financial Sustainability: As a clinical-stage company with no approved products or product revenues, Inventiva has incurred significant losses since inception. It requires additional capital to continue operations; failure to secure financing could force curtailment of programs or threaten its status as a going concern.
- External Factors: Risks include geopolitical events (conflicts in Russia/Ukraine and the Middle East), health epidemics, and macroeconomic conditions affecting clinical trial initiation and completion.
- Closing Conditions: The issuance of T1 bis Securities is expected on December 19, 2024, subject to customary closing conditions.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds of the T1 bis Transaction.
- Confirm the impact of the SUSAR on the NATiV3 trial enrollment and timeline.
- Monitor the Company's cash runway and any announcements regarding subsequent tranches of the Multi-Tranche Financing.
- Review the composition of the Board of Directors following the appointment of new members and the resignation of prior directors.
- Assess the Company's ability to meet the December 31, 2025 deadline for nominating additional investor-proposed Board members.